---
title: "United Laboratories Wins Green Light for Trial of Once-Weekly Insulin UBT38006"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285527106.md"
description: "United Laboratories International Holdings (HK:3933) has received approval from China's National Medical Products Administration for a clinical trial of its innovative long-acting insulin, UBT38006. This drug aims for once-weekly dosing, enhancing patient adherence and quality of life for diabetics. The approval is seen as a significant milestone in the company's diabetes portfolio and biopharmaceutical innovation. Analysts rate the stock as a Buy with a target price of HK$20.00, reflecting confidence in the company's strategic focus on chronic disease therapies."
datetime: "2026-05-07T10:10:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285527106.md)
  - [en](https://longbridge.com/en/news/285527106.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285527106.md)
---

# United Laboratories Wins Green Light for Trial of Once-Weekly Insulin UBT38006

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

The latest announcement is out from The United Laboratories International Holdings ( (HK:3933) ).

The United Laboratories International Holdings announced that China’s National Medical Products Administration has approved a clinical trial application for UBT38006 Injection, a self-developed Class 1 innovative long-acting insulin from its subsidiary The United Bio-Technology (Hengqing). Designed with a novel molecular structure that allows reversible binding to human albumin, the drug is intended to deliver a once-weekly dosing regimen by significantly extending its half-life.

The company expects UBT38006 to improve medication adherence for diabetic patients, reduce the burden of frequent injections, and enhance overall quality of life, if successfully developed. Management framed the approval as a major milestone in its diabetes portfolio and a step toward strengthening its competitiveness and innovation in the biopharmaceutical sector, underscoring a continued strategic focus on chronic disease therapies and value creation for shareholders.

The most recent analyst rating on (HK:3933) stock is a Buy with a HK$20.00 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.

**More about The United Laboratories International Holdings**

The United Laboratories International Holdings is a Cayman Islands-incorporated pharmaceutical group listed in Hong Kong, focusing on biopharmaceuticals and chronic disease treatments such as diabetes. Through wholly owned subsidiaries like The United Bio-Technology (Hengqing), the company develops innovative drug candidates aimed at improving patient adherence and clinical outcomes.

**Average Trading Volume:** 10,269,062

**Technical Sentiment Signal:** Hold

**Current Market Cap:** HK$19.04B

For a thorough assessment of 3933 stock, go to TipRanks’ Stock Analysis page.

### Related Stocks

- [03933.HK](https://longbridge.com/en/quote/03933.HK.md)

## Related News & Research

- [Assessing United Laboratories International Holdings (SEHK:3933) Valuation After Dupilumab Biosimilar Trial Approval](https://longbridge.com/en/news/285448082.md)
- [What Madrigal Pharmaceuticals (MDGL)'s Wider Q1 Losses and Rezdiffra Revenue Momentum Mean For Shareholders](https://longbridge.com/en/news/286674743.md)
- [When Can We Expect A Profit From Island Pharmaceuticals Limited (ASX:ILA)?](https://longbridge.com/en/news/286861950.md)
- [How Strong UGN-103 Phase 3 Durability Data At UroGen Pharma (URGN) Has Changed Its Investment Story](https://longbridge.com/en/news/286658162.md)
- [Alaunos Reports Preclinical Aln1003 Data Showing Effects On Insulin-Resistance-Related Biomarkers And Liver Histology In Diet-Induced Obesity Models](https://longbridge.com/en/news/286776760.md)